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Abstract 29 
Tetanus (TeNT) and botulinum (BoNT) neurotoxins, the causative agents of tetanus and 30 
botulism, respectively, are the most potent toxic molecules known to mankind. This extreme 31 
potency is attributed to: i) their specificity for essential components of the neurotransmitter 32 
release machinery present at vertebrate synapses, and ii) their high-affinity targeting to motor 33 
neurons by binding to polysialogangliosides and protein receptors. Comprising the clostridial 34 
neurotoxin family, TeNT and BoNTs engage distinct surface receptors and intracellular 35 
sorting pathways in neurons. BoNTs bind to the intraluminal domain of specific synaptic 36 
vesicle proteins that are exposed to the extracellular milieu upon exocytosis, and are taken 37 
up by synaptic vesicle recycling. A sizeable proportion of BoNT molecules remain at the 38 
neuromuscular junction, where their protease moiety is released into the cytoplasm, blocking 39 
synaptic transmission and causing flaccid paralysis. In contrast, TeNT undergoes binding to 40 
specific components of the basal membrane at the neuromuscular junction, is endocytosed 41 
into motor neurons and sorted to axonal signalling endosomes. Following this, TeNT is 42 
transported to the soma of motor neurons located in the spinal cord or brainstem, and then 43 
transcytosed to inhibitory interneurons, where it blocks synaptic transmission. TeNT-induced 44 
impairment of inhibitory input leads to hyperactivity of motor neurons, causing spastic 45 
paralysis, which is the hallmark of tetanus. This review examines the molecular mechanisms 46 
leading to the entry, sorting and intracellular trafficking of TeNT and BoNTs. 47 
 48 
Highlights 49 
 Tetanus and botulinum neurotoxins undergo long range traffic in mammalian neurons 50 
 Signalling endosomes and autophagomes mediate the transport of these neurotoxins 51 
 The binding of tetanus toxin to the basal membrane is key for its uptake in neurons 52 
 53 
1. Historical background 54 
Tetanus (TeNT) and botulinum (BoNT) neurotoxins have been studied intensely over the last 55 
century, while BoNTs have attracted worldwide attention in the last 25 years for their ever-56 
increasing medical applications. These neurotoxins are produced by Clostridium tetani and 57 
various serotypes of Clostridium botulinum, which together form the clostridial neurotoxin 58 
(CNT) family. The unmistakable clinical symptoms of tetanus toxicity were first reported in 59 
Egyptian and Indian documents before 1500 BC. It was Hippocrates (460–370 BC) who 60 
coined the term τετανοσ (translated to ‘tension’ in Ancient Greek) to describe these 61 
symptoms when studying the progressive spastic paralysis developed by a sailor as a 62 
consequence of an injury caused while handling the anchor of his boat (Udwadia, 1994). 63 
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However, the aetiology of tetanus remained a mystery until the end of the 19th century, when 64 
the efforts of Carle and Rattone in Turin, Nicolaier in Göttingen and Kitasato in Berlin led to 65 
the conclusion that tetanus was a transmissible disease caused by an anaerobic sporigenic 66 
bacterium present in the soil (Udwadia, 1994). Although Nicolaier was able to report the 67 
presence of a strychnine-like substance in the supernatant of these bacterial cultures, it was 68 
Faber in 1890 who isolated TeNT and demonstrated its physiological role as the causative 69 
agent of the spastic paralysis observed during tetanus (Udwadia, 1994). Importantly, the 70 
availability of methods to isolate TeNT subsequently allowed Marie in 1897, and Meyer, 71 
Ranson and others thereafter to demonstrate that TeNT was able to reach the central 72 
nervous system (CNS), mediating its central affects after travelling along peripheral motor 73 
nerves (Habermann, 1989; Marie, 1897; Udwadia, 1994). These findings, thus, set the stage 74 
for the modern analyses of CNT trafficking in neurons.  75 
Botulism, characterised by a general muscle weakness, was described independently in the 76 
same period as TeNT by Kerner (1822), followed by the isolation of C. botulinum and the first 77 
serotype of BoNT by van Ermengem in 1895 (van Ermengem, 1979). Traditionally seven 78 
BoNT serotypes have been described in the literature including BoNT/A, BoNT/B, BoNT/C, 79 
BoNT/ D, BoNT/E, BoNT/F, and BoNT/G (Montal, 2010; Poulain et al., 2015; Pirazzini et al., 80 
2017). However, most recently, an eighth BoNT serotype has been discovered and named 81 
BoNT/X (Zhang et al., 2017). Each individual serotype contains multiple subtypes of toxins 82 
(e.g., BoNT/A1, BoNT/A2, etc.) (Poulain et al., 2015) with unique activities, synaptic targets 83 
and downstream intracellular signalling (Pirazzini et al., 2017). 84 
These discoveries, together with the isolation of different C. botulinum toxigenic strains and 85 
studies on their intracellular activity and synaptic targets of TeNT and BoNTs in the 1990s 86 
(Montal, 2010; Pirazzini et al., 2017), have revealed important insights into a complex protein 87 
machinery responsible for the neuronal targeting, uptake and inhibition of synaptic 88 
transmission by these neurotoxins. As a consequence, the study of the mode of action of 89 
TeNT and BoNTs continue to have direct impact on several disciplines, including 90 
microbiology, pharmacology, physiology, cell biology, biochemistry and molecular medicine. 91 
TeNT and BoNTs have been used as tools of discovery in bioscience to dissect the 92 
mechanisms of regulated secretion and intracellular trafficking, and as CNS-targeting 93 
molecules for DNA vaccines and therapeutics (Behzadi et al., 2016; Toivonen et al., 2010). 94 
The need for further in-depth characterisation of the mechanism of action of these 95 
neurotoxins both in vitro and in vivo is further highlighted by the widespread use of BoNTs to 96 
treat pathologies beyond the classical area of synaptic hyperactivity, such as chronic 97 
migraine, depression and aesthetic/dermatological applications (Pirazzini et al., 2017). In 98 
contrast, tetanus continues to claim the lives of thousands of individuals per year, including 99 
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many newborns affected by tetanus neonatorum 100 
(http://apps.who.int/gho/data/view.main.1520_46) making the development of efficient 101 
countermeasures an urgent priority. 102 
 103 
2. Mechanism of Action 104 
TeNT displays lethal dose, 50% (LD50) ranging between 0.1 and 5 ng/kg of body weight in 105 
mice (Gill, 1982), while the BoNT LD50 lies between 0.1 and 500 ng/kg (Pirazzini et al., 106 
2017). The LD50 for both neurotoxins, however, can greatly vary in different species (Gill, 107 
1982). There are many factors that determine the precise time of symptom onset (i.e., 108 
paralysis) after CNT intoxication, including dose, route of application and species. For TeNT, 109 
the incubation period between the initial injury and the onset of clinical symptoms is highly 110 
variable (from 1-2 days to a couple of months) (Udwadia, 1994) and includes the time 111 
needed for the spores to germinate into vegetative bacteria, which, after autolysis, 112 
presumably release the neurotoxin into the bloodstream. Shorter incubation periods are 113 
usually associated with TeNT of higher severity, in which the symptoms reach their peak in 114 
7-10 days, plateau for 1-2 weeks and gradually decline in additional 1-2 weeks, although 115 
muscle stiffness may persists for weeks or even months after recovery (Udwadia, 1994). 116 
BoNTs, on the other hand, are typically released into the body via food contaminated by 117 
spores, in which the storage conditions allowed their germination and the expression of the 118 
progenitor toxin complex formed by BoNTs and non-toxic neurotoxin-associated proteins 119 
(NAPs). NAPs comprise a non-toxic non-haemagglutinin component (NTNHA) that plays an 120 
important role in protecting BoNTs from the harsh gastrointestinal tract, and other subunits 121 
that enable binding to the surface of intestinal cells for subsequent transcytosis of the 122 
neurotoxic complex from the apical membrane to the basolateral membrane of intestinal 123 
epithelium (Amatsu et al., 2013; Gu et al., 2012; Lee et al., 2013; Lee et al., 2014; Sugawara 124 
et al., 2014; Yao et al., 2014). Once released, the BoNT progenitor complex sequesters E-125 
cadherin in its monomeric form, blocking E-cadherin dimer formation, thus weakening the 126 
trans-epithelial barrier (Lee et al., 2014; Sugawara et al., 2014). This process leads to bulk 127 
entry of neurotoxin into the bloodstream and can accelerate intoxication. 128 
After entering the general circulation, TeNT and BoNTs bind with high affinity to the 129 
presynaptic membrane of the motor neuron at the neuromuscular junction (NMJ) where they 130 
are rapidly internalised (Montal, 2010; Rummel, 2016) (Figure 1A). BoNTs mainly remain at 131 
the NMJ and inhibit the release of the excitatory neurotransmitter acetylcholine (Figure 1), 132 
blocking muscle excitation-contraction coupling and thus causing a flaccid paralysis. In 133 
contrast, TeNT enters motor neuron axon terminals through endocytosis at the NMJ (Figure 134 
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1B) and is predominantly retrogradely transported in axonal signalling endosomes to the 135 
soma of motor neurons in the spinal cord (Schmieg et al., 2014) (Figure 1C). TeNT is 136 
subsequently transcytosed into inhibitory interneurons where it blocks neuroexocytosis 137 
through the cleavage of the SNARE VAMP/synaptobrevin, thus inhibiting neurotransmitter 138 
release from intoxicated interneurons to motor neurons (Figure 1D). As a consequence, the 139 
balance between excitatory and inhibitory inputs to motor neurons is disrupted, eliciting 140 
hyperactive motor neurons and spasticity. In addition to inhibitory interneurons (i.e., 141 
glycinergic and GABAergic), excitatory interneurons (i.e., glutamatergic and cholinergic) also 142 
respond to TeNT application but with different sensitivity and effects (Bergey et al. 1987; 143 
McMahon et al., 1992; Williamson et al. 1992; Shin et al., 2012). This preference for 144 
inhibitory versus excitatory synapses is maintained when TeNT is applied directly into the 145 
CNS and underlie the neurodegenerative and epileptogenic effects of TeNT (Bagetta et al., 146 
1990; Bowery et al., 1992; Ferecsko et al., 2015), which may result from unopposed release 147 
of glutamate from excitatory central synapses. 148 
Paradoxically, despite TeNT and BoNTs exert opposing influences on skeletal muscle (i.e., 149 
spasticity versus flaccidity), their modes of action are quite similar. Indeed, both CNT family 150 
members block neurotransmitter release via specific cleavage of soluble NSF-attachment 151 
protein receptor (SNARE) proteins involved in neuroexocytosis (Montecucco et al., 2005). 152 
The differences in clinical symptoms arise from preferential site of action in different neurons 153 
(Montal, 2010; Rummel, 2016) (Figure 1).  154 
Interestingly, the hallmarks of TeNT and BoNT have also been observed in neurons other 155 
than motor neurons, including cortical, sensory and sympathetic neurons (Blum et al., 2014; 156 
Cordero-Erausquin et al., 2009). 157 
 158 
3. Multi-domain structure and function 159 
TeNT and BoNTs are remarkably similar in sequence and structure (Montal, 2010). The 150 160 
kDa single-chain proteins are cleaved by proteases producing an active neurotoxin 161 
comprising two chains of 100 kDa (heavy or H chain) and 50 kDa (light or L chain), which 162 
remain associated via non-covalent interactions and a conserved inter-chain disulphide bond 163 
essential for neurotoxicity (de Paiva et al., 1993; Pirazzini et al., 2014; Schiavo et al., 1990). 164 
The heavy chain is further subdivided into two 50 kDa domains: the amino terminal (HN) and 165 
carboxy terminal (HC) domains (Montal, 2010). X-ray crystallography of BoNT/A (Garcia-166 
Rodriguez et al., 2007; Lacy et al., 1998; Stevens et al., 1991), BoNT/B (Swaminathan and 167 
Eswaramoorthy, 2000), BoNT/E (Kumaran et al., 2009) and TeNT (Masuyer et al., 2017) was 168 
used to confirm the spatial orientation of these domains relative to each other. TeNT and 169 
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BoNT/E assume a more compact/closed arrangement, with the HC domain interacting closely 170 
with the L chain and HN, although distinct interaction surfaces are employed by the two CNTs 171 
(Kumaran et al., 2009; Masuyer et al., 2017). Conversely, BoNT/A and BoNT/B display an 172 
elongated arrangement of the three domains, which are largely separated, with the exception 173 
of an extended loop in the amino-terminus of the H chain (termed belt), which is wrapped 174 
around the L chain.  175 
The HC domain of CNTs is responsible for their neuron-specific binding and is composed of 176 
two sub-domains of roughly the same size (Pirazzini et al., 2017). While the amino-terminal 177 
sub-domain (HCN) is structurally similar to the carbohydrate-binding domain of the lectin 178 
family, the carboxy-terminal sub-domain (HCC) is homologous to domains involved in protein-179 
protein interactions (Montal, 2010; Pirazzini et al., 2017). It is in the HCC loops of CNTs where 180 
the highest degree of sequence and structural divergence lies (Lacy and Stevens, 1999), 181 
which ultimately contributes to binding specificity. Crucially, in BoNT/A and BoNT/E, the HC 182 
domain is isolated from the remaining part of the molecule, allowing full access of all surface 183 
loops for binding. The close conformation found in BoNT/E and TeNT may instead impose 184 
some steric constraints to the full accessibility of HC to protein and lipid receptors (Kumaran 185 
et al., 2009; Masuyer et al., 2017). Moreover, other portions of TeNT may contribute to 186 
enhanced clearance from the NMJ and wider spreading into spinal cord neurons (Ovsepian 187 
et al., 2015). 188 
The HC domains of CNTs bind to polysialogangliosides on the plasma membrane, in 189 
particular to G1b gangliosides, with high specificity and affinity (Montecucco, 1986), although 190 
binding to other gangliosides series has been reported (e.g. BoNT/A interacts with GQ1b and 191 
GT1b, but also to GD1a, albeit with lower affinity) (Kitamura et al., 1980; Takamizawa et al., 192 
1986). Binding to polysialogangliosides is facilitated by oligosaccharide-binding sites (one 193 
and two, in BoNTs and TeNT, respectively) in the HCC sub-domain of the heavy chain 194 
(Rummel, 2016; Rummel et al., 2003). Mutations in the carbohydrate binding domain 195 
abrogate binding of these toxins to neuronal plasma membranes, thus highlighting the 196 
importance of this interaction (Rummel, 2016). Addition of the polysialoganglioside GT1b to 197 
NMJs protects the neuron from the toxic effects of BoNT via competitive inhibition and 198 
partially abolishes the retrograde transport of TeNT (Stoeckel et al., 1977). In addition, 199 
removal of sialic acid residues from the plasma membrane by neuraminidase treatment 200 
(Bigalke et al., 1986) or blocking ganglioside biosynthesis (Kitamura et al., 2005; Rummel, 201 
2013; Williamson et al., 1999) inhibits CNT activity. Despite the strong requirement of surface 202 
polygangliosides for uptake of CNTs, it is clear that they are not unique determinants of 203 
binding since TeNT and BoNTs do not compete with each other for internalisation at the 204 
NMJ. Additional protein receptor(s) have therefore been suggested to act in conjunction with 205 
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gangliosides, referred to as the dual receptor hypothesis (Montecucco, 1986; Rummel, 2016; 206 
Rummel et al., 2007). According to this hypothesis, polysialogangliosides act in one of two 207 
ways: i) recruit TeNT and BoNTs to specific regions of the plasma membrane, which are 208 
locally enriched in a certain protein receptor, or ii) maintain a specific conformational state of 209 
these toxins so as to enable the receptor to bind. In line with this hypothesis, specific protein 210 
co-receptors have been identified for most CNTs (see section 4). 211 
The pH-dependent translocation of the L-chain from the endocytic lumen into the cytosol is 212 
mediated by the amino-terminal part of the H chain (HN). HN is composed of a belt closely 213 
interacting with the L chain and a central portion containing two very long α-helices (Montal, 214 
2010; Pirazzini et al., 2016). Although the function of this domain in membrane insertion was 215 
first described in the 1980s, the exact mechanism underlying the transfer of the L chain to 216 
the cytosol remains, at least in part, controversial (Montal, 2010; Pirazzini et al., 2016). 217 
Recent findings have demonstrated that the reduction of the disulphide bridge linking the H 218 
and L chains by the thioredoxin reductase-thioredoxin (TrxR-Trx) system is required for the 219 
release of the L chain into the cytosol, and inhibition of TrxR-Trx activity prevents the 220 
intoxication of neurons both in vitro and in vivo (Pirazzini et al., 2015; Pirazzini et al., 2014; 221 
Zanetti et al., 2015). Reduction of the interchain disulphide bridge is strictly coupled to L 222 
chain refolding, since the inhibition of cytosolic chaperone Hsp90 reduces the intracellular 223 
activity of BoNTs (Azarnia Tehran et al., 2017). Interestingly, Hsp90 and TrxR-Trx physically 224 
interact on the surface of SVs, where they orchestrate a chaperone-redox complex likely to 225 
be involved in synaptic protein refolding, which is exploited by the L chains of CNTs to enter 226 
the cytosol (Azarnia Tehran et al., 2017). 227 
The L chain contains the catalytic zinc atom and is responsible for the intracellular 228 
endopeptidase activity of CNTs, which is directed towards the SNARE proteins 229 
VAMP/synaptobrevin 1-3 (BoNT/B, BoNT/D, BoNT/F, BoNT/G, BoNT/HA and BoNT/X, 230 
TeNT), SNAP25 (BoNT/A, BoNT/C and BoNT/E) and syntaxin-1 (Montal, 2010; Pirazzini et 231 
al., 2016; Zhang et al., 2017). BoNT/X also cleaves the non-canonical substrates VAMP4, 232 
VAMP5 and Ykt6 (Zhang et al., 2017). The number of zinc atoms that bind to the L chain 233 
varies among different CNTs; while the L chains of TeNT, BoNT/A, BoNT/B and BoNT/F 234 
chelate one atom of zinc (Schiavo et al., 1992a; Schiavo et al., 1992b; Schiavo et al., 1993), 235 
BoNT/C binds two atoms of zinc with different affinities (Breidenbach and Brunger, 2005; 236 
Garcia-Rodriguez et al., 2007; Schiavo et al., 1995). The protease activity of the L chain can 237 
be abolished by heavy metal chelators, such as ortho-phenantroline, thus generating inactive 238 
apo-neurotoxins (Bhattacharyya and Sugiyama, 1989; Schiavo et al., 1992a). The zinc atom 239 
is chelated by two histidines located in the endopeptidase motif (His-Glu-x-x-His); the 240 
glutamic acid residue in this motif binds the water molecule necessary for the catalysis (third 241 
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ligand), with another glutamic acid (Glu261 in BoNT/A) acts as the fourth ligand (Montal, 242 
2010; Pirazzini et al., 2016). 243 
 244 
4. Neuron-specific binding 245 
CNTs are exquisitely neuron-specific and able to bind neurons in vivo at concentrations in 246 
the sub-nanomolar regime (Simpson, 2000). Both BoNTs and TeNT interact with the 247 
peripheral cholinergic nerve terminals, while TeNT also binds to sympathetic and adrenergic 248 
nerve fibres (Rossetto et al., 2001). The HC domains are largely responsible for this high-249 
affinity binding, since paralysis caused by native toxins can be counteracted by recombinant 250 
HC proteins (Lalli et al., 1999; Rummel et al., 2009). Additional targeting information, 251 
however, may be encoded elsewhere in the full length neurotoxin (Ovsepian et al., 2015). 252 
The neuron-specificity of CNTs is also likely to reflect the complexity of their cellular 253 
receptors, which are most probably composed of multiple lipid and protein components 254 
forming arrays of presynaptic receptors (APRs) (Montecucco et al., 2004). 255 
Polysialogangliosides play a key role in the binding and internalisation of CNTs at the 256 
presynaptic membrane, presumably due to their high concentration at the NMJ and their 257 
lateral mobility. Interaction of the toxin with polysialogangliosides allows its subsequent 258 
interaction with other molecules in the APRs, thus leading to virtually irreversible binding. In 259 
addition to polysialogangliosides, APRs contain lipids such as cholesterol and 260 
sphingomyelin, GPI-anchored protein(s) and other membrane-bound protein(s) (Montecucco 261 
et al., 2004). Interestingly, both TeNT and BoNT/A have been found to bind sphingomyelin-262 
enriched membrane microdomains (Herreros et al., 2001; Muraro et al., 2009); additionally, 263 
BoNT/A and BoNT/C interact with phosphoinositol lipids (Muraro et al., 2009; Tsukamoto et 264 
al., 2005; Zhang and Varnum, 2012). Since BoNTs and TeNT have been proposed to bind 265 
distinct co-receptors, the APRs recognised by BoNTs would direct them inside vesicles that 266 
are acidified within the NMJ, such as recycling synaptic vesicles (SVs), whereas the APRs 267 
binding to TeNT would sort this neurotoxin into signalling endosomes undergoing axonal 268 
retrograde transport towards the neuronal soma (Schmieg et al., 2014). 269 
Several lines of evidence indicate that BoNTs enter the NMJ by exploiting the process of SV 270 
recycling (Montal, 2010; Pirazzini et al., 2017). Accordingly, many CNTs bind to the 271 
intraluminal domain of SV proteins, which are exposed to the extracellular milieu upon SV 272 
exocytosis (Figure 1B). BoNT/B, BoNT/D, BoNT/C and BoNT/G interact with the calcium-273 
sensing proteins synaptotagmin-1 and/or -2 (reviewed in Rummel, 2016). Multiple isoforms of 274 
the synaptic vesicle protein-2 (SV2) function as the protein receptors for BoNT/A, BoNT/E 275 
and BoNT/F (Rummel, 2016), whilst BoNT/C and BoNT/D seem to utilize only gangliosides 276 
 9 
as host cell receptors (Karalewitz et al., 2012). Due to its recent discovery, no protein 277 
receptor has been described for BoNT/X (Zhang et al., 2017). Crucially, Harper et al. found 278 
that BoNT/A is internalised in a SV subpopulation that is not destined for recycling, 279 
highlighting the existence of functional heterogeneity between SV pools (Harper et al., 2016).  280 
BoNT/A, similar to TeNT, is able to enter neurons when SV recycling is blocked (Restani et 281 
al., 2012a), suggesting that BoNT/A could potentially use alternative entry route(s) targeting 282 
this neurotoxin to sites other than the NMJ (Figure 1B). In agreement, BoNT/A has been 283 
shown to be retrogradely transported in hippocampal, tectal and motor neurons and undergo 284 
transcytosis in the visual system (Bomba-Warczak et al., 2016; Mazzocchio and Caleo, 285 
2015). Additionally, BoNT/A accumulates in dorsal root ganglia upon injection in the bladder 286 
(Papagiannopoulou et al., 2016). Although SV2A can potentially undergo long-range 287 
transport in spinal cord motor neurons (Debaisieux et al., 2016), other protein receptors may 288 
be involved in this process. One such protein whose endogenous trafficking route might be 289 
exploited by BoNT/A is the fibroblast growth factor receptor-3 (FGFR3). Although 290 
controversial (Weisemann et al., 2016), FGFR3 has been shown to bind BoNT/A (Jacky et 291 
al., 2013). FGFR3 undergoes receptor-mediated endocytosis (Haugsten et al., 2011) and 292 
has been identified in the proteome of axonal signalling endosomes (Debaisieux et al., 293 
2016), thus suggesting an alternative transport route for BoNT/A. On the other hand, BoNT/A 294 
might bind to the basal membrane at the NMJ, as recently reported for TeNT (Bercsenyi et 295 
al., 2014), leading to its sorting to axonal signalling endosomes and transcytosis. 296 
To reach its final site of action, TeNT must enter two different types of neurons: a motor 297 
neuron innervating skeletal muscle followed by an inhibitory interneuron of the spinal cord 298 
(Figure 1A,B,D). Post-internalisation, TeNT is sorted to different intracellular pathways, 299 
hence it is expected to bind to distinct receptors in these neurons. Several lines of evidence 300 
indicate that TeNT and BoNTs are internalised via different routes. First, TeNT at 301 
physiological concentrations does not block synaptic transmission at the NMJ, unlike BoNTs. 302 
Second, if TeNT binding sites were present in recycling SVs, then an increase in the rate of 303 
neuronal stimulation should lead to increased binding of the toxin to the membrane. This, 304 
however, is not observed. While high frequency stimulation increases the rate of TeNT 305 
intoxication, it does not enhance binding of the toxin to the NMJ (Schmitt et al., 1981). Third, 306 
the abrogation of exocytosis and neurotransmitter release from NMJs by BoNT treatment 307 
does not affect the uptake and retrograde axonal transport of TeNT (Habermann and 308 
Erdmann, 1978). Fourth, TeNT exhibits temperature-sensitive binding and internalisation; 309 
while fully functional at 25°C, it is inactive on NMJs at 18°C even in the presence of high-310 
frequency stimulation and massive neurotransmitter release (Schmitt et al., 1981). 311 
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Due to the presence of two ganglioside-binding sites in the HC domain of TeNT, it was 312 
proposed to rely solely on lipid binding for its cellular entry (Chen et al., 2009). Cis-313 
interactions of gangliosides have been suggested to play an important role in mediating 314 
binding of the neurotoxin to target cells (Rinaldi et al., 2009). However, since 315 
polysialogangliosides are not uniquely distributed at the NMJ and are not readily internalised 316 
(Deinhardt et al., 2006a), TeNT would require additional factors to enter into motor neurons. 317 
One of the proteins described to interact with TeNT is Thy-1, an abundant GPI-anchored 318 
protein (Herreros et al., 2001). However, Thy-1 is unlikely to be the main protein receptor on 319 
motor neurons in vivo because mice lacking Thy-1 remain sensitive to the toxic effects of 320 
TeNT (Herreros et al., 2001). TeNT enters motor neurons together with the neurotrophin 321 
receptors TrkB and p75NTR (Deinhardt et al., 2006b; Terenzio et al., 2014a; Terenzio et al., 322 
2014b), and its internalisation is dependent on neurotrophin signalling. Interestingly, TeNT 323 
interacts with specific basal membrane components at the NMJ to stimulate uptake of TrkB 324 
and formation of signalling endosomes (Bercsenyi et al., 2014). In particular, the HC domain 325 
of TeNT (HCT) directly binds to nidogen-1 and -2 (also known as entactin-1 and -2) and 326 
selectively targets NMJs rich in nidogen-2. A small peptide derived from nidogen-1 blocks 327 
TeNT uptake in motor neurons and at NMJs, and protects mice from TeNT-induced paralysis 328 
(Bercsenyi et al., 2014). Nidogen-2 knockout mice are less sensitive to tetanus intoxication 329 
and show TeNT-mediated botulism-like symptoms (Bercsenyi et al., 2014), which are also 330 
observed when TeNT is injected in wild type animals at high doses (Matsuda et al., 1982). 331 
Taken together, these results suggest that TeNT and BoNTs might share common entry 332 
routes when key basal membrane components required by TeNT are absent or when its 333 
preferred internalisation pathway is overloaded. Accordingly, addition of recombinant 334 
nidogen-1 decreases the co-localisation of HCT with SV2A and increases its rate of 335 
internalisation, whilst at high concentrations, HCT preferentially enters SV2A-positive 336 
organelles (Bercsenyi et al., 2014). Although controversial (Blum et al., 2012), TeNT was 337 
also shown to bind SV2 in hippocampal neurons and relied on this interaction for cell entry 338 
(Yeh et al., 2010). 339 
The identification of protein co-receptors for TeNT at the NMJ provides crucial information on 340 
this trafficking pathway from the NMJ to spinal cord interneurons, offering new strategies for 341 
the delivery of therapeutics into the spinal cord. Furthermore, it provides new insights into the 342 
alternative trafficking pathway used by BoNT/A to elicit responses in the CNS (Caleo and 343 
Schiavo, 2009). Although further studies are required to determine whether BoNTs engage 344 
with basal membrane components, these findings open the possibility that extracellular 345 
matrix-derived peptides might be used to mitigate some of the undesired long-range effects 346 
of BoNT/A therapy in humans. 347 
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 348 
5. Neuronal internalisation and axonal transport 349 
Endocytosis of CNTs is an active process: their cellular entry is temperature- and energy-350 
dependent and is differentially modulated by synaptic activity (Baldwin and Barbieri, 2007; 351 
Blum et al., 2014; Pirazzini et al., 2017; Rummel et al., 2009). At physiological 352 
concentrations, uptake of both CNTs occurs via distinct mechanisms with TeNT 353 
internalisation predominantly occurring through clathrin-mediated endocytosis whilst BoNTs 354 
exploit SV recycling (Blum et al., 2012; Deinhardt et al., 2006a; Montal, 2010). TeNT 355 
internalisation is dependent on a specific subset of clathrin adaptors, which target the 356 
neurotoxin to non-acidified endosomal compartments (Bohnert and Schiavo, 2005), thus 357 
preventing the translocation of the L chain into the cytoplasm of the motor neuron and 358 
enabling its arrival in a fully active form to spinal cord inhibitory interneurons. Internalisation 359 
of BoNT/A and TeNT is partially abrogated by dynamin inhibitors (Deinhardt et al., 2006a; 360 
Harper et al., 2011) or dynamin mutant overexpression (Deinhardt et al., 2006a), in 361 
agreement with the established role of dynamins in the fission of clathrin-coated vesicles 362 
from the plasma membrane. 363 
Although TeNT and its atoxic H chain fragment (HCT) uptake in motor neurons is largely 364 
unaffected by membrane depolarisation (Deinhardt et al., 2006a), their mechanism of entry in 365 
central neurons is likely to be dependent on SV recycling. Experiments by Blum et al. 366 
indicate that HCT entry in cortical neurons is stimulated by membrane depolarisation (Blum et 367 
al., 2014), validating previous results that show TeNT internalisation in hippocampal neurons 368 
follows SV re-uptake (Matteoli et al., 1996). However, subtle differences may exist between 369 
HCT and TeNT uptake and trafficking in cortical and spinal cord neurons, as recently reported 370 
(Blum et al., 2014). 371 
Post-internalisation, TeNT must undergo long-range transport to reach the soma of motor 372 
neurons, from where it undergoes trans-synaptic transfer into inhibitory interneurons. In order 373 
to achieve this, it exploits endogenous microtubule-based axonal transport pathways which 374 
the neuron uses to communicate between the synapse and the soma (Goldstein and Yang, 375 
2000) (Figure 1C). This highly regulated, long-range axonal transport is facilitated by two 376 
classes of microtubule-dependent molecular motors: cytoplasmic dynein and kinesins. 377 
Cytoplasmic dynein motor proteins are responsible for moving cargo in the retrograde 378 
direction from axonal terminals to the cell body, where the minus ends of microtubules are 379 
located. In contrast, kinesin motor proteins are responsible for delivering their cargo in the 380 
anterograde direction toward the plus end of microtubules that are located in synaptic 381 
terminals or growth cones (Hirokawa et al., 2010; Vale, 2003). Despite the majority of 382 
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transport dynamics involving microtubules (Hirokawa et al., 2010), actin-based motors (e.g., 383 
myosins) also contribute and hence, some form of interactions between the microtubule- and 384 
actin-mediated transport systems has been suggested (Hirokawa et al., 2010; Vale, 2003). 385 
Cytoplasmic dynein plays a particularly crucial role in the retrograde transport of TeNT to the 386 
soma (Lalli et al., 2003; Schiavo et al., 2013) (Figure 1C). In vivo studies using mice carrying 387 
a mutation in cytoplasmic dynein heavy chain showed deficits in axonal retrograde transport 388 
of HCT, which are associated with motor and sensory neuron degeneration (Hafezparast et 389 
al., 2003). Functional axonal transport is crucial for the development and maintenance of the 390 
nervous system, and impairments in this process are associated with neurodegenerative 391 
conditions, such as amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease and 392 
acquired peripheral neuropathies (De Vos and Hafezparast, 2017; Schiavo et al., 2013). 393 
However, for cargo to bind, dynein must form a complex with dynactin and this formation is 394 
dependent on the Bicaudal D (BICD) family of adaptor proteins that are enriched at the 395 
minus-end of microtubules (Carter et al., 2016; Hoogenraad and Akhmanova, 2016). 396 
Underpinning their importance, BICD1 is involved in the trafficking of TeNT and neurotrophin-397 
receptor complexes (Schmieg et al., 2014; Terenzio et al., 2014b) and mutations in the 398 
homologous BICD2 have been shown to cause spinal muscular atrophy (Oates et al., 2013; 399 
Rossor et al., 2015).  400 
The retrograde transport of HCT takes place in axonal signalling endosomes, which contain 401 
neurotrophins, their receptors and other proteins (Deinhardt et al., 2006b; Lalli and Schiavo, 402 
2002). To create a functional physical map of these organelles, our laboratory has developed 403 
a method based on magnetic iron oxide nanoparticles coupled to HCT, which enable the 404 
purification of signalling endosomes from embryonic stem cell-derived motor neurons and 405 
their quantitative mass spectrometry analysis (Debaisieux et al., 2016; Deinhardt et al., 406 
2006b; Wade et al., 2012). We found that HCT-positive organelles undergo rapid maturation 407 
with the acquisition of late endosomal markers, and are specifically enriched in proteins 408 
known to be involved in neurodegenerative diseases and neuroinfection (Debaisieux et al., 409 
2016). The maturation of signalling endosomes is dependent upon Rab5, which is involved in 410 
sorting after internalisation, followed by Rab7, which is involved in the fast retrograde 411 
transport of HcT (Figure 1C) as well as neurotrophin-receptor complexes (Deinhardt et al., 412 
2006b; Salinas et al., 2009). A functional cross-talk between HCT and neurotrophins is 413 
emerging, since the application of exogenous brain-derived neurotrophic factor (BDNF) 414 
results in an increase in the internalisation of HcT at the NMJ as well as accumulation of HcT 415 
in the sciatic nerve (Roux et al., 2006). However, the sharing of axonal signalling endosomes 416 
by other virulence/pathological factors such as canine adenovirus-2, cholera toxin, poliovirus, 417 
Borna virus and pseudotyped lentivirus with neurotrophin receptors suggests that despite 418 
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different methods of internalisation, a common mechanism for sorting and retrograde 419 
transport may exist (Charlier et al., 2016; Hislop et al., 2014; Ohka et al., 2009; Salinas et al., 420 
2009).  421 
In contrast to the acidic pH found in the lumen of the majority of endosomes, axonal transport 422 
carriers containing HCT display neutral pH. The pH of signalling endosomes is critical, as 423 
acidification in TeNT and BoNTs carriers triggers the translocation of the enzymatically active 424 
subunit (i.e., L chain) into the cytosol. Endosomal acidification also causes the dissociation of 425 
neurotrophin-receptor complexes, terminates their en route signalling and targets the 426 
endosome for degradation. Such tight regulation of the pH is dependent on the vacuolar 427 
ATPase complex (Bohnert and Schiavo, 2005). Therefore, the maintenance of neutral pH of 428 
TeNT carriers enables its presentation to interneurons in a fully active form to consequently 429 
mediate the disruption of synaptic communication.  430 
In contrast to the historical view that BoNTs only disrupt communication at the NMJ, several 431 
studies provide evidence of long-range trafficking and CNS expression of BoNT after 432 
intramuscular injections (reviewed in Caleo and Schiavo, 2009; Mazzocchio and Caleo, 433 
2015). Indeed, BoNT/A was first detected in the spinal cord ventral horn after injections in the 434 
gastrocnemius muscle (Wiegand et al., 1976). Its presence was also detected in diaphragms 435 
after intraperitoneal injections of BoNT/A and /B (Black and Dolly, 1986). In this context, 436 
higher BoNT/A levels were observed in the axoplasm of myelinated axons, suggestive of 437 
differences in the uptake and sorting mechanisms of different BoNT serotypes (Black and 438 
Dolly, 1986). Experiments comparing the effects of BoNT/A and /E applied to the distal 439 
neurites of primary sympathetic neurons cultured in compartmentalised chambers revealed 440 
that whilst most BoNT/A and /E cleaved SNAP25 near the sight of uptake, a small fraction 441 
also cleaved SNAP25 in their soma, albeit at different rates (Lawrence et al., 2012). In 442 
addition, Restani et al. have demonstrated that BoNT/A undergoes fast axonal retrograde 443 
transport whereas BoNT/E exhibited slower axonal retrograde transport with a greater 444 
frequency of pausing and short periods of anterograde transport in primary motor neurons 445 
(Restani et al., 2012a). This study suggests that BoNT/E is coupled with a less efficient 446 
mechanism of long-range trafficking and may explain, in part, why BoNT/E cannot mediate 447 
similar effects in the CNS, despite having the same intracellular targets as BoNT/A. 448 
Furthermore, these data also suggest that the serotype and concentration of BoNTs are also 449 
key factors in local (i.e., NMJ) versus distant (i.e., soma) effects. These results were 450 
confirmed in hippocampal neurons grown in microfluidic devices, where BoNT/A and BoNT/D 451 
were found to be taken up into non-acidified organelles undergoing axonal retrograde 452 
transport to the soma (Bomba-Warczak et al., 2016). After internalisation, their activities were 453 
detected in upstream neurons, thus indicating that BoNT/A, BoNT/D and TeNT may undergo 454 
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interneuronal transfer in an active form in vitro (Bomba-Warczak et al., 2016). Interestingly, 455 
Wang et al. found that a significant proportion of HC fragment of BoNT/A (HCA) was 456 
incorporated into LC3-positive autophagosomes in hippocampal neurons, which then 457 
underwent retrograde transport to the cell soma. Blocking autophagosome formation or 458 
acidification inhibited the activity-dependent retrograde trafficking of HCA, suggesting a role 459 
for presynaptic autophagosomes in long distance transport of BoNT/A (Wang et al., 2015). 460 
Elements of this process have been recapitulated in vivo by studies demonstrating the 461 
retrograde transport of BoNT/A and HCA in spinal cord motor neurons (Antonucci et al., 462 
2008; Restani et al., 2012a; Restani et al., 2012b; Wang et al., 2015) and sensory neurons 463 
(Fan et al., 2017; Hong et al., 2017; Matak et al., 2014; Papagiannopoulou et al., 2016). 464 
Taken altogether, these investigations provide evidence that BoNTs also undergo retrograde 465 
transport to the CNS, the consequences of which are yet to be entirely understood. 466 
 467 
6.0 Future perspectives 468 
Since TeNT and BoNTs are capable of being sorted to the axonal retrograde trafficking route 469 
and undergo interneuronal transfer in vivo, it has been proposed that non-toxic fragments of 470 
CNTs may be used as targeting agents for the delivery of therapeutics, such as recombinant 471 
proteins and/or DNA, into the CNS (Toivonen et al., 2010). Chimeras of HCT and various 472 
proteins have been shown to be successfully internalised and undergo axonal retrograde 473 
transport, maintaining their enzymatic activity upon delivery to the targeted area (Francis et 474 
al., 2004a). Importantly, these HCT fusion proteins were shown to transfer across synapses 475 
in vivo (Coen et al., 1997), access second and higher-order neurons (Miana-Mena et al., 476 
2003) and deliver their payload to the neuronal cytosol, when fused to translocation-477 
competent proteins (e.g. diphtheria toxin) (Francis et al., 2004b).  478 
Due to their diverse biological activities, neuronal growth factors have frequently been used 479 
as biological payloads. BDNF and glial cell line-derived neurotrophic factor (GDNF) fused 480 
with HCT have been found to have neuroprotective effects in animal models of ALS (Calvo et 481 
al., 2011; Ciriza et al., 2008) and Parkinson’s disease (Larsen et al., 2006). Fusion of 482 
cardiotrophin-1 and HCT also promoted motor neuron survival (Bordet et al., 2001), whilst a 483 
chimera of the anti-apoptotic factor Bcl-XL and HCT decreased apoptosis induced by 484 
glutamate-mediated excitotoxicity (Carlton et al., 2008). BDNF has also been targeted to 485 
neurons by nanoparticles made of polyethylene imine linked to HCT (Oliveira et al., 2010). 486 
Protein engineering has been explored to re-target BoNTs to different neuronal populations 487 
by using a self-assembling 'protein stapling' technology (Ferrari et al., 2013). BoNT/A lacking 488 
its HCA domain as well as HCT were produced separately and then linked by exploiting the 489 
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high-affinity interaction of paired SNARE motifs (Ferrari et al., 2013). The stapled chimera 490 
was found to lack peripheral paralytic effects, and significantly reduce the enhanced 491 
nociceptive sensitivity found in animal models of inflammatory, surgical, and neuropathic pain 492 
(Mangione et al., 2016). 493 
Whilst these studies have explored the potential of recombinant protein chimeras, a few 494 
attempts have been made to directly express these fusion proteins by delivering exogenous 495 
DNA. In particular, Moreno-Igoa et al. showed that a single intramuscular administration of 496 
naked-DNA encoding GDNF-HCT significantly delayed the onset of symptoms, ameliorate 497 
the functional deficits and extended the lifespan of a mouse model of ALS (Moreno-Igoa et 498 
al., 2012). HCT might thus represent a valuable strategy to deliver therapeutics to the CNS by 499 
exploiting its high tropism for motor neurons and its ability to undergo axonal retrograde 500 
transport and transcytosis. In addition, DNA fusion vaccines encoding a portion of HCT 501 
coupled with tumour antigen sequences is highly immunogenic against colon carcinoma 502 
(Behzadi et al., 2016). 503 
Several studies have also highlighted the intrinsic ability of HCT to protect neurons from 504 
neurodegeneration in a variety of animal models, including chemically induced Parkinson’s 505 
disease (Mendieta et al., 2009), ALS (Moreno-Igoa et al., 2010) and spinal muscular atrophy 506 
(Olivan et al., 2016). This property may be linked to the ability of HCT to activate the 507 
neurotrophin receptor signalling cascade, including ERK1/2 and Akt, via a mechanism still 508 
not completely understood (Gil et al., 2003; Gil et al., 2001). HCT co-localises with the 509 
neurotrophin receptors TrkB and p75NTR in axonal signalling endosomes (Deinhardt et al., 510 
2006a; Lalli and Schiavo, 2002), yet it is unclear whether HCT signalling is physiologically 511 
relevant and whether it would negatively or positively regulate axonal retrograde transport. 512 
However, recent results from Wang et al. demonstrate that TrkB activation couples synaptic 513 
activity with the retrograde flux of axonal signalling endosomes, thus suggesting that HCT 514 
and TeNT regulate their own sorting and/or retrograde transport (Wang et al., 2016).  515 
In addition to their importance as virulence factors and biotherapeutics, BoNTs, TeNT and 516 
their recombinant fragments are also becoming increasingly popular as key tools of 517 
discovery to uncover deficits of axonal transport in animal models of neurological diseases 518 
(Bilsland et al., 2010; LeRoux et al., 2014; Malik et al., 2011; Schafer et al., 2017; Sleigh et 519 
al., 2017a; Sleigh et al., 2017b), ageing (Sleigh and Schiavo, 2016) and as flexible trans-520 
synaptic tracers (Coen et al., 1999; Kumar and Boehm, 2014).  521 
Several important questions centred on the trafficking of BoNTs and TeNT are still 522 
unaddressed. First and foremost, the nature of the receptor complex targeting TeNT and 523 
BoNTs to axonal signalling endosomes at the NMJ need to be elucidated at the molecular 524 
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level, together with the exact role of neurotrophin signalling (or other signalling cascades) in 525 
this process. This line of research would help the identification of the minimal requirements 526 
for the efficient sorting of these neurotoxins to proximal and/or distal sites of action. This 527 
information would be important for basic and clinical scientists to direct the in vivo activity of 528 
BoNTs, thus improving their clinical specificity and limiting their side effects. Further research 529 
is also necessary to define the neuronal receptors of the expanding family of BoNT subtypes 530 
(Peck et al., 2017) and their preferential site of action in vivo. This in turn would allow the 531 
selection of novel BoNT subtypes endowed with unique pharmacodynamics and 532 
pharmacokinetics properties ideal for specific clinical applications (e.g. chronic pain, short 533 
term treatment in post-operative management). In this way, the travel diaries of TeNT and 534 
BoNTs would become not just a fascinating reading for molecular and cellular 535 
neurobiologists, but a very useful roadmap for pharmacologists and clinical neuroscientists to 536 
understand, navigate and treat the human nervous system. 537 
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Figure legend 927 
Figure 1. Trafficking of the tetanus (TeNT) and botulinum neurotoxins (BoNT) in vivo 928 
(adapted from Schmeig et al., 2014b). A. Anatomical connections between skeletal 929 
muscles, spinal cord motor neurons and their afferent cells. Motor neurons innervate 930 
skeletal muscles via the neuromuscular junction (NMJ). The motor neuron axon is 931 
myelinated and can reach over a meter in length in humans. The motor neuron soma is 932 
located in the spinal cord, where it forms contacts with adjacent interneurons and upper 933 
motor neurons. B. Internalisation at the NMJ. Both TeNT (T; in blue) and BoNTs (B; in 934 
green) accumulate in the synaptic space of the NMJ, which is filled with basal lamina (in 935 
yellow). TeNT binds to polysialogangliosides and nidogens, and this complex is targeted to 936 
the axonal retrograde transport route (solid blue arrow). At higher doses or with the 937 
unavailability of nidogens, TeNT is able to bind SV2 and can enter synaptic vesicle (SV) 938 
recycling at the NMJ (thinner blue arrow) (Bercsenyi et al., 2014). The majority of BoNT 939 
molecules remain at the NMJ (solid green arrow), where they cleave synaptic SNAREs, 940 
thereby blocking the fusion of (SVs) containing acetylcholine and causing flaccid paralysis. 941 
However, a fraction of BoNT/A may enter organelles targeted to the soma (thinner green 942 
arrow), such as axonal signalling endosomes (Restani et al., 2012a) or autophagosomes 943 
(Wang et al., 2015). C. Axonal retrograde transport. TeNT is transported to the soma via 944 
axonal signalling endosomes, along with neurotrophins and their receptors. This long-range 945 
retrograde axonal transport, which also requires the GTP-bound form of the small GTPase 946 
Rab7 (in purple) (Deinhardt et al., 2006b), is dependent on the microtubule-based motor, 947 
cytoplasmic dynein (in red). D. Interneuronal transfer of TeNT into inhibitory 948 
interneurons. Once in the motor neuron soma in the spinal cord (Bilsland et al., 2010), 949 
TeNT is released into the extracellular medium and is internalised by SV recycling into 950 
inhibitory interneurons, where it cleaves VAMP/synaptobrevin, thereby blocking inhibitory 951 
neurotransmission. This impairs the balance between inhibitory and excitatory afferents on 952 
the motor neurons, leading to disruptions in co-ordinated muscle contraction and spastic 953 
paralysis. 954 
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